Residency: University of Southern California, 2005
Fellowship: National Institutes of Health, 2008
Master's: Duke University School of Medicine, 2009
Fellowship: University of California, San Diego School of Medicine, 2011
The research of Mazen Noureddin, MD, focuses on the underlying mechanisms of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), new imaging modalities and exploring new treatments. He has conducted several original studies that have been featured in publications such as Gastroenterology, Hepatology and The American Journal of Gastroenterology, among many others. The Fatty Liver Program at Cedars-Sinai has many breakthrough clinical trials targeting new therapies in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitisn (NASH), including those with advanced fibrosis and cirrhosis.
Copyright © 2020 Malibu Microbiome Meeting - All Rights Reserved.
CME activities are jointly provided by Medical Resource Association, Inc. and AKH Inc., Advancing Knowledge in Healthcare. AKH, Inc. is proud to have received Accreditation with Commendation from the Accreditation Council for Continuing Medical Education.
Please contact Charles Messal 941-726-8425 or Kristen M. Beury 941-726-3169 regarding any CME Activity related questions. Thank you!
*Agenda/Topics/Speakers subject to change without notice